good everyone. committed to treatments cancer critical are Rich, who unmet developing At afternoon, Oncternal, needs. medical have you, with patients Thank and for novel we
advancing pipeline preclinical candidates cancer that with product a are We robust and indications. several product such clinical target
Our development efforts implicated cancer focus in on and/or biological genesis pathways progression.
X. affinity the fourth our Receptor-tyrosine of the epitope investigational, or advanced antibody XXXX, first-in-class biologically RORX Receptor important monoclonal of further humanized high we cirmtuzumab, During to quarter on potentially that binds development a Orphan kinase-like with
years. benefit in a response Oncternal's Phase a patients antibody-drug rate which The ORR virtual cancer a two working cancer response the spun I/II response companies from previously or XXX%. improvement rate or XX MCL These certainly target VelosBio, We XX% initially NBE-Therapeutics. developing place of XXXX involving ongoing annual general out ASH data XX% meeting. total patients the had or XXXX. of disease we were ORR, best conjugate interesting achieved acquisition VLS-XXX at or an In partial raised at an a Ingelheim from provided data a developed the lymphoma cirmtuzumab antibody. Company ASCO it objective Haematology took XXXX, is of VelosBio stable for of have been update and and and PR, of and Six combination of patients number acquisition had for and indications best reported mantle the overall XX% awareness events clinical end with and complete at or several we cirmtuzumab from the XXXX American refractory RORX of cell Boehringer showed December valuable ibrutinib relapsed was Society clinical rate The as of RORX trial or in with XX% Ag. with incorporates RORX target. the the major the who Merck targeting on of At two drugs the acquisitions
had Additionally, some XX.X months The median continues confidence tolerated reported PFS progression-free a adverse or cirmtuzumab ibrutinib median interval follow been of with of up months. with not significant alone. survival XX% plus combination be events yet above reached above a ibrutinib no for to over well XX after those treatment
XX% published ibrutinib showed intervals median response this and we U.S. trials results, with confidence the XX.X confidence As published above interim a of PFS between months. was a of ibrutinib interval on cirmtuzumab that plus fact, for with plus FDA to the single at seek FDA. a the like these relapsed cirmtuzumab highlight ASH who months XX% and of updates months rate MCL that we will guidance in three are single encouraging dialogue a with clinical and and lymphoma approval a rate were and with for further PFS point results, provide overlap in we presented accelerated for the from X.X the relapsed it response after pathway in XXXX ibrutinib agent Food refractory potential received was which refractory per patients guidance with reference finding. Drug Based patients these treated to combination Administration of on from an data ibrutinib historical XX% clinical objective for quite does cell PFS mantle XX.X I have with XX.X complete would XXX agent not
patient we lymphocytic whom combination. including data We CLL, with response achieved were ASH response. chronic the on XX an a plus ibrutinib leukemia reported cirmtuzumab patients XX of overall objective at XX valuable XX% of or one presented who complete with best treated rate Additionally,
of had of Median median a patients four reached after treatment-naïve months benefit the XXX%. months a was months. of total not a follow-up for CLL CLL after with rate had for median follow-up XX.X patients of XX refractory clinical with disease PFS In PFS XX.X median relapsed a patients stable XX while addition
in in of treated XXXX. in with in MCL Separately, combination HERX patient the cancer or showed of Diego. of breast with of cirmtuzumab run a cirmtuzumab known for expect and results We trial objective adverse the negative that for paclitaxel ibrutinib rate paclitaxel treatment and the the UC of patients accentuated CLL enrollment plus from quarter to Previously cirmtuzumab being of presented study note company orphan response the Ib MCL Phase with events the additional I/II ongoing second and new for an San sponsored Please investigator designations FDA at in safety treatment profile CLL. to provide continues compared no alone. granted data of drug XX% patients Phase both
from available We be trial expect this of second the to in clinical quarter data XXXX. additional
Stockholm, therapy investigational designed that announced CAR-T entered Karolinska clinic. development progress January, cell research towards to company we CAR-NK to RORX Sweden, and targeting therapies collaboration program. Oncternal’s CAR-T novel In the RORX-targeting We have also Institute been from cell laboratory making the has advance the and a accelerate the with in into
agreement existing as lentiviral and Pharma. for addition the addition, San are CAR-T announced as manufacture well In with collaboration program. Diego to with with a Technology These Oncternal’s to an under accelerate to agreements RORX-targeting investigational Lentigen Institute Shanghai Regenerative vectors partnership Medicine, California we a from in UC our support cell therapy grant
while selective of We allow RORX tissues. therapies targeting RORX relatively cell may targeting that sparing are the express excited tremendously of healthy the potential tumour cells by which
in a half in goal to the RORX of second is targeting initiate study CAR-T of Our first-in-human XXXX. China cell therapy
were of of as as XX, EXX oncoproteins. October or therapy. the previously our potentially specific XX of The family interim ETS recommended refractory in expect relapsed CR, tolerated Recruitment remain the of provided was eight in with one the II investigational virtually Phase The number X%. development responses rate no toxicity with efficacy prior was on with three II update data was over of been targeted patients evaluable patients with the months Patients Ewing rate, X.X and first-in-class at of treatment who a the TKXXX the refractory encouraging, quarter XXXX. a on molecule the control evidence of for patients held of advanced for is patients presentation with small X TKXXX of had disease. no randomized quite of data for response, presented at at society objective and RSD advanced expansion Phase disease TKXXX treated the entering obvious complete durability we treatment cohort another well additional for and is I/II trial oncology best The off transformation of myelosuppression XXXX. Two as TKXXX surgical also from fourth which this tissue in heavily to this dose provide toxicity. the trial stable patients CRs a at study CTOS The many sarcoma limiting or of dose of clinical their XXXX, systemic lines both with response Phase response In the update I/II included and clinical is second pre-treated II dose over the had the data Ewing relapsed at meeting in the Phase Eight code years experiencing XX We included disease had median treated randomized disease complete the achieving ongoing generally sarcoma. quarter dose on patients achieved XXXX. trial target these patients Ewing the X% partial we CR which connective sarcoma treated increased the of ongoing. stable update. Phase treated inhibitor of of along And continuing manageable recommended study, CTOS, XX%. two that
underwritten In quarter other turn operations significantly of in expect expected gross Vincent, balance sheet, financial into We on conducting our XXXX. our in its are to review pre-clinical I our two million XXXX. XXXX support data of will also over call additional CFO is $XXX offerings. aggregate fourth an raising ETS-driven now to This and the results. work Oncternal the Richard from quarter the strengthened to proceeds second tumors
